科兴制药(688136) - 2025 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2025 reached CNY 154,115.64 million, a year-on-year increase of 9.54%[4] - Net profit attributable to shareholders of the parent company was CNY 15,944.12 million, representing a significant increase of 406.47% compared to the previous year[4] - Operating profit rose to CNY 17,183.37 million, marking a 171.89% increase year-on-year[4] - The basic earnings per share increased to CNY 0.81, up 406.25% from CNY 0.16 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 5,970.62 million, a 69.36% increase year-on-year[4] Asset and Return Metrics - Total assets at the end of the reporting period were CNY 354,408.60 million, reflecting a 12.08% increase from the beginning of the period[4] - The weighted average return on net assets improved to 9.47%, an increase of 7.53 percentage points compared to the previous year[4] Revenue Sources - The company achieved strong growth in overseas revenue, contributing to the overall increase in operating income[7] Non-Recurring Items - Non-recurring gains and losses increased significantly due to changes in the fair value of private equity funds held by the company[7] - The company has not yet obtained the audit report for its private equity fund, which may impact the final net profit figures[8]